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Background: Atrial fibrillation (AF) is critical for hypertrophic cardiomyopathy (HCM) patients since at risk not only for heart failure but 
also ischemic embolism. However, AF is often asymptomatic and not always diagnosed before occurrence of embolic events. Here, 
we investigated HCM patients with long-term followed-up to evaluate a risk of embolic events in HCM patients with or without pre-
documented AF.
methods: 354 consecutive HCM patients (51±14 years, 60% male) with preserved LV systolic function were enrolled and retrospectively 
followed. The primary end point was an acute cerebral or systemic embolism.
results: During 14±12 year follow-up, the ischemic embolism occurred in 53 patients, in which 22 (42%) patients were diagnosed AF 
before the events, while 20 were diagnosed AF after the events. Anticoagulation, warfarin(average time in therapeutic range 47%) was 
prescribed for 23 (6%) of all patients at baseline and for 17 (32%) of 53 patients at embolic events. The incidence of the ischemic embolism 
did not differ between patients with and without pre-diagnosed AF before the stroke or systemic embolism. Among patients without 
pre-diagnosed AF (n=211), univariate analysis revealed that age (HR:1.03, [95%CI: 1.01-1.06] p=0.003), history of syncope (2.41,[1.01-
5.07],p=0.04), hypertension (2.63, [1.40-5.18]p=0.003), diabetes mellitus (2.16 [1.09-4.10], p=0.03), and increased LV end-systolic 
diameter (1.05,[1.00-1.10] p=0.04) were associated with the embolic events. Even if AF was not documented, higher CHADS2 score was 
significantly associated with risk of the embolic events.
conclusion:  Despite higher incidence of stroke or systemic embolic risk in HCM, anticoagulation was prescribed in a limited number of 
patients since AF was not always documented before the events, suggesting that either AF is diagnosed or not, anticoagulation might be 
beneficial for prevention of ischemic embolism in patients with HCM and CHADS2 ≥1.
